Clinical Trial

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.
Protocol Amendment History 6 changes
notable Trial sites expanded: 192 -> 195 locations 2026-08-11
notable Trial sites expanded: 187 -> 192 locations 2026-07-30
notable Trial sites expanded: 173 -> 187 locations 2026-07-09
notable Trial sites expanded: 167 -> 170 locations 2026-05-12
notable Trial sites expanded: 164 -> 167 locations 2026-04-24
notable Trial sites expanded: 155 -> 164 locations 2026-04-16
Trial Details
NCT Number NCT06943872
Lead Sponsor BeOne Medicines
Collaborators: German CLL Study Group
Conditions Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Enrollment 630 participants
Start Date 2025-06-11
Primary Completion 2029-09-30 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-10